Abstract
The use of anti-gene agents to disrupt the expression of disease-related genes could potentially be of utility in the treatment of a large number of illnesses, including most neoplasms. Traditional anti-gene agents include antisense oligonucleotides and ribozymes. Recent observations have provided evidence for another promising anti-gene technology-RNA interference (RNAi), in which the introduced double-stranded RNA (dsRNA), after a complicated series of processing steps, disrupts the expression of the targeted cellular gene. Further studies have indicated that small interfering RNAs (siRNAs) of generally 21 ∼ 23 nucleotides, which resemble the processing products of long dsRNA, can induce RNAi directly in mammalian cells. Because of their high specificity and efficiency, siRNAs might be a new class of anti-gene medicines for gene therapy applications.
Keywords: Gene Therapy, anti-gene medicines, oligonucleotides, ribozymes
Current Gene Therapy
Title: Small Interfering RNA: A New Tool for Gene Therapy
Volume: 3 Issue: 5
Author(s): Feng Bi, Na Liu and Daiming Fan
Affiliation:
Keywords: Gene Therapy, anti-gene medicines, oligonucleotides, ribozymes
Abstract: The use of anti-gene agents to disrupt the expression of disease-related genes could potentially be of utility in the treatment of a large number of illnesses, including most neoplasms. Traditional anti-gene agents include antisense oligonucleotides and ribozymes. Recent observations have provided evidence for another promising anti-gene technology-RNA interference (RNAi), in which the introduced double-stranded RNA (dsRNA), after a complicated series of processing steps, disrupts the expression of the targeted cellular gene. Further studies have indicated that small interfering RNAs (siRNAs) of generally 21 ∼ 23 nucleotides, which resemble the processing products of long dsRNA, can induce RNAi directly in mammalian cells. Because of their high specificity and efficiency, siRNAs might be a new class of anti-gene medicines for gene therapy applications.
Export Options
About this article
Cite this article as:
Bi Feng, Liu Na and Fan Daiming, Small Interfering RNA: A New Tool for Gene Therapy, Current Gene Therapy 2003; 3 (5) . https://dx.doi.org/10.2174/1566523034578203
DOI https://dx.doi.org/10.2174/1566523034578203 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Effect of Dietary Supplementation of Black Seed (N. Sativa L.) on Lipid Profile of Patients Suffering from Diabetes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Back to the Future: COX-2 Inhibitors for Chemoprevention and Cancer Therapy
Mini-Reviews in Medicinal Chemistry Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT
Current Medicinal Chemistry Dimethyl Sulfoxide as an Excitatory Modulator and its Possible Role in Cancer Pain Management
Inflammation & Allergy - Drug Targets (Discontinued) Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry Adipose Tissue: The Link Between Obesity and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Construction of an M1GS Ribozyme for Targeted and Rapid mRNA Cleavage; Application on the Ets-2 Oncogene
Medicinal Chemistry Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro Studies
Current Drug Targets Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014
Current Drug Targets Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics Models of Infection Before and After Stroke: Investigating New Targets
Infectious Disorders - Drug Targets NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Natural and Synthetic Coumarin Derivatives with Anti-Inflammatory / Antioxidant Activities
Current Pharmaceutical Design Role of Free Radicals and Antioxidant Signaling in Skeletal Muscle Health and Pathology
Infectious Disorders - Drug Targets Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Interleukin 1-beta is Linked to Chronic Low-Grade Inflammation and Cardiovascular Risk Factors in Overweight Adolescents
Endocrine, Metabolic & Immune Disorders - Drug Targets